• Japanese
  • Korean
  • Chinese
Cover Image

Radiopharmaceuticals

This report analyzes the worldwide markets for Radiopharmaceuticals in US$ Million by the following Product Segments: Diagnostic Radiopharmaceuticals, and Therapeutic Radiopharmaceuticals. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2010 through 2018. Also, a six-year historic analysis is provided for these markets. The report profiles 69 companies including many key and niche players such as Actinium Pharmaceuticals, Inc., Advanced Medical Isotope Corporation, Alseres Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals, Bracco Diagnostics, Inc., Cardinal Health, Inc., Covidien Plc, Eli Lilly and Company, Erigal Limited, EUSA Pharma (Europe) Ltd., GE Healthcare, IBA Group, Immunomedics, Inc., Jubilant Life Sciences Limited, Lantheus Medical Imaging Inc., Medi-Radiopharma Ltd., Nordion Inc., Peregrine Pharmaceuticals, Inc., PETNET Solutions Inc., Positron Corporation, Singapore Radiopharmaceuticals Pte Ltd., and Triad Isotopes, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
  • Disclaimers
  • Data interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • A. Diagnostic Radiopharmaceuticals
    • B. Therapeutic Radiopharmaceuticals

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • A Quick Primer
  • Market Scenario: Recession and the Road Ahead
  • Recession: A Period of Global Decline
  • The Road to Recovery
  • Outlook
  • Impact of Healthcare Budget Cuts in Developed Economies: A Review
  • Diagnostic Radiopharmaceuticals: The Dominant Segment
  • Promising Developments in Therapeutic Radiopharmaceuticals Underway

2. GROWTH DRIVERS & TRENDS

  • New Therapeutic Radiopharmaceuticals to Drive Global Market
  • Improvements in Imaging Technology
  • Rise in International Investments for Radiopharmaceuticals
  • Bayer Algeta Partnership for Alpharadin
  • Lutathera
  • AREVA Med
  • AtlabPharma and Cornell Well Medical Center
  • Zevalin's Landmark FDA Approval Offers New Opportunities
  • Improved Reimbursement for Therapeutic Radiopharmaceuticals
  • Rise in Cancer Incidences & Access to Modern Therapeutics Foster Growth
  • World Cancer Statistics - Incidence and Mortality Data
    • Table 1: World Cancer Incidence by Geographic Region and Gender (2012): Number of New Cancer Cases Reported in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 2: World Cancer Mortality by Geographic Region and Gender (2012): Number of Cancer- Related Deaths in Thousands for Asia-Oceania, Europe, North America, Latin America & the Caribbean, and Africa (includes corresponding Graph/Chart)
    • Table 3: Global Incidence of Common Cancers in Men (2012): Number of New Cases Reported in Thousands for Lung & Bronchus, Prostate, Colorectal and Liver Cancers (includes corresponding Graph/Chart)
    • Table 4: Global Incidence of Common Cancers in Women (2012): Number of New Cases Reported in Thousands for Breast, Colorectal, Lung & Bronchus and Liver Cancers (includes corresponding Graph/Chart)
    • Table 5: Global Cancer Mortality in Men for Select Cancers (2012): Number of Deaths in Thousands for Lung & Bronchus, Liver, Colorectal and Prostate Cancers (includes corresponding Graph/Chart)
    • Table 6: Global Cancer Mortality in Women for Select Cancers (2012): Number of Deaths in Thousands for Breast, Lung & Bronchus, Colorectal and Liver (includes corresponding Graph/Chart)
    • Table 7: World Breast Cancer Statistics: Top 20 Countries with Highest Breast Cancer Rates (includes corresponding Graph/Chart)
  • Cancer Prone Sites based on Age
  • Targeted Radionuclide Therapy: Gaining Ground in Cancer Treatment
  • Intra-operative Lymphatic Mapping (ILM): Creating New Opportunities for Radiopharmaceuticals in Cancer Detection
  • Emergence of Radioisotope Based Personalized Therapy Bodes Well for the Market
  • Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance
  • Widespread Awareness among Practitioners & Patients: The Need of the Hour
  • Cardiology: An Important Sector for Radiopharmaceuticals
  • Expansion of Molecular Imaging Platform is Key to Future Growth
  • Battling Alzheimer's Disease - A Powerful Market Force
    • Table 8: Elderly Population (65+ Years) as a Percentage of the Total Population: 2000 & 2025 (includes corresponding Graph/Chart)
  • Growing Demand for PET to Drive up Demand
  • Opportunities Increasing for Fluorine-Based Myocardial Perfusion Agents
  • Innovative PET Biomarkers in the Offing for Oncology
  • Hypoxia Imaging Presents Opportunities for PET
  • Introduction of SPECT/CT & PET/CT: Double Edged Weapons for Growth
  • Targeted Peptides & Alpha Emitters: The New Frontiers of Therapeutic Radiopharmaceuticals
  • International Collaborations Give a Thumbs Up to Drug Development
  • Key Statistical Data
    • Table 9: Worldwide Market for 99Mo (2010): Percentage Share Breakdown of Weekly Demand by Region (includes corresponding Graph/Chart)
    • Table 10: Worldwide Market for 99Mo (2010): Percentage Share Breakdown of Production by Reactor (includes corresponding Graph/Chart)
  • Reactors Producing Cobalt 60 & Molybdenum 99
    • Table 11: Global Projected Demand for Mo-99 in Emerging and Mature Markets for the Years 2020 and 2030 (includes corresponding Graph/Chart)

3. MARKET CHALLENGES

  • High Costs of Drug Development Piques Manufacturers
  • Supply Shortages: A Niggling Cause of Concern
  • Canadian Scientists Discover Means to Address Supply Shortages
  • Price Sensitivity & Competition from Alternatives Limit Market Potential
  • Lack of Dosage Standards for Pediatric Patients Limits Radiopharmaceutical Efficacy
  • Unfounded Fears of Radiation Exposure Hinder Growth
  • Bottlenecks in Developing Markets

4. THERAPEUTIC RADIOPHARMACEUTICAL PRODUCTS UNDER DEVELOPMENT

  • Primer
  • Lutathera for Neuroendocrine Cancer
  • Alpharadin for Bone Cancer Treatment
  • Actimab for Leukemia and Blood Borne Cancers
  • Lead-212 Alpha Therapy for Metastasized Abdominal Cancers
  • Lu-177-J591 PSMA Antibody for Prostate Cancer
  • Indium-111-Pentetreotide for Neuroendocrine Tumors
  • Yttrium-90 Clivatuzumab for Pancreatic Cancer
  • CycloSam for Bone Cancer
  • Phospholid Ether Tumor Targeting

5. IMAGING AGENTS - AN OVERVIEW

  • A Quick Primer
  • Growth Drivers
  • Market Restraints
  • Significance of Technological Advancements
  • X-Ray Contrast Media: Giving Way to Emerging Modalities
  • Medical Reimbursement: A Critical Factor
  • Market Structure
  • Select Players by Segment

6. NUCLEAR MEDICINE - AN OVERVIEW

  • Nuclear Medicine - An Introduction
  • Growth Drivers in a Nutshell
  • Market Shifts to Hybrid Imaging

7. PRODUCT OVERVIEW

  • Radiopharmaceuticals: A Definition
  • Mechanism of Action
  • Application of Radiopharmaceuticals
  • Radioactive Tracers for Diagnostic Imaging
  • Therapeutics
  • Research
  • Sterilization
  • Classification of Radiopharmaceuticals
  • Diagnostic Radiopharmaceuticals
    • Commonly Used Diagnostic Radiopharmaceutical Agents
    • Major Isotopes and their Diagnostic Applications
      • Advantages
      • Classification
      • Cardiology Diagnostics
      • Non-cardiology Diagnostics
  • Molecular Imaging Modalities in Radiopharmaceutical Diagnostics
    • Planar Imaging
    • Positron Emission Tomography (PET)
      • Advantages
      • Applications of PET
      • Commonly used Radioisotopes in PET Scans
    • Major PET Isotopes and their Applications
    • Single Photon Emission Computed Tomography (SPECT)
      • Applications of SPECT
      • Commonly used Radioisotopes in SPECT Scans
  • Therapeutic Radiopharmaceuticals
  • Characteristics of Therapeutic Radiopharmaceuticals
  • Commonly used Therapeutic Agents
    • Major Isotopes and their Therapeutic Applications
  • Radiopharmaceuticals for Thyroid Therapy
  • Radiopharmaceuticals for Cancer Therapy
  • Radiopharmaceuticals for Neuroendocrine Tumors
  • Radiopharmaceuticals for Radiosynoviorthesis Therapy
  • Radiopharmaceuticals for Bone Pain Palliation Therapy
  • Radiopharmacy: A Key Link in the Distribution Chain
    • Table 12: US Radiopharmacies Market (2010): Percentage Share Breakdown of SPECT Doses Sold by Company (includes corresponding Graph/Chart)

8. PRODUCT INNOVATIONS/INTRODUCTIONS

  • Positron Launches Advanced PosiRx Pharmacy Automation Systems
  • BARC Launches Indigenous Radiopharmaceuticals- Powered Scans
  • Rapidscan Pharma Solutions EU and GE Healthcare Unveil Rapiscan®
  • Positron Launches PosiRx

9. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST- A PERSPECTIVE BUILDER

  • GE Healthcare Enhances Radiopharmaceuticals Product Portfolio
  • IBA Molecular Obtains Positive Opinion to Market Dopacis in Europe
  • BARC Develops Radiopharmaceuticals for Cancer Treatment
  • Medrad Mounts Intego™ PET Infusion System at UPMC
  • IBA Molecular Announces the Launch of Cyclone ® 18 Twin
  • Molecular Insight Develops New Radio-iodinated Molecules
  • Immunomedics Develops New Antibody for Radio-immunotherapy

10. RECENT INDUSTRY ACTIVITY

  • Advanced Accelerator Applications Expands Radiopharmaceutical Manufacturing Network
  • Advanced Accelerator Applications Inks Partnership Agreement with Uwrc Spoka Z Ograniczon Odpowiedzialno Ci
  • Eli Lilly to Purchase Two Radiopharmaceutical Imaging Agents from Siemens
  • UPPI Inks Contract with Novation
  • Dalton Inks Manufacturing Partnership with Clarity Pharmaceuticals
  • Lantheus Medical Imaging Extends Agreement with Nordion
  • Lantheus Medical Imaging and Jubilant HollisterStier Enter into Agreement
  • NCM Reveals New Advanced PET Radiopharmaceutical Manufacturing Center
  • Turkey Inaugurates First Particle Accelerator
  • SK Capital and IBA Sign Agreement to Setup IBA Molecular Imaging
  • Novelos Therapeutics Pockets Cellectar Inc
  • Southern Research Institute Inks Agreement with Biomedical Research Foundation
  • IBA Acquires Minority Stake in PET Net Solutions
  • Amerinet Inks Group Purchasing Agreement with Positron
  • Premier Purchasing Partners Awards Supplier Contract to Lantheus Medical Imaging
  • MDS Nordion Inks Collaborative Agreement with Avid Radiopharmaceuticals
  • Devicor™ Medical Products Acquires Neoprobe®
  • UHN and CPDC Form Joint Venture
  • AstraZeneca Inks Licensing Agreement with Neoprobe
  • Cardinal Health Unveils Molecular Imaging Collaboration Center in Phoenix Region

11. CORPORATE ACTIVITY IN THE RECENT PAST - A PERSPECTIVE BUILDER

  • Covidien Enters into Agreement with IAE POLATOM
  • Dalat Nuclear Research Institute Inks Agreement with Probactive Biotech
  • Principio Wins Licensing Agreement from Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
  • Covidien Inks Definitive Agreement with Triad Isotopes
  • Eli Lilly Inks Merger Agreement with Avid Radiopharmaceuticals
  • Lumiphore Inks Agreement with Algeta
  • IBA Renews Contract with Servicio Andaluz de Salud
  • Lumiphore and Algeta Ink Partnership Agreement
  • Positron and Covidien Ink Agreement
  • PETNET Solutions Expands PET Radiopharmaceutical Network
  • Triad Isotopes Acquires Radiopharmacy Network of Covidien
  • Principio Receives Exclusive Technological Development License from Hopkins Sidney Kimmel Comprehensive Cancer Center
  • PETNET Solutions Renews Supply Agreement with Paul Strickland Scanner Centre
  • IBA Molecular Obtains Marketing Approval for Filtracis Radiopharmaceutical Kit
  • DHA Inks MoU with DCD
  • Algeta Signs Agreement with Bayer
  • Antisoma Collaborates with Bryan Oncor
  • Karpov Institute Enters into Collaboration with MDS Nordion
  • MDS Nordion Establishes Glucotrace Facility
  • Draximage Inks Agreement with Guerbet
  • Eczacybathorny-Monrol Collaborates with IBA
  • Siemens Healthcare Signs Agreement with Calypso Medical
  • Molecular Insight Signs Agreement with BioMedica Life Sciences
  • Bayer Schering Signs Agreement with Algeta
  • IBA Inks Agreement with Aposense
  • Draxis Receives Approval from Health Canada for Generic Sestamibi
  • Cyclopharm and Alfred Health Solutions Form Joint Venture
  • Guerbet Inks Distribution Agreement with Draximage
  • Ion Beam Applications Collaborates with EczacIbasI-Monrol Nuclear Products

12. FOCUS ON SELECT PLAYERS

  • Actinium Pharmaceuticals Inc (US)
  • Advanced Medical Isotope Corporation (US)
  • Alseres Pharmaceuticals, Inc (US)
  • Bayer HealthCare Pharmaceuticals Inc (US)
  • Bracco Diagnostics, Inc. (US)
  • Cardinal Health, Inc (US)
  • Covidien Plc (Ireland)
  • Eli Lilly and Company (US)
  • Erigal Limited (UK)
  • EUSA Pharma (Europe) Ltd. (UK)
  • GE Healthcare (UK)
  • IBA Group (Belgium)
  • Immunomedics, Inc. (US)
  • Jubilant Life Sciences Limited (India)
  • Lantheus Medical Imaging Inc (US)
  • Medi-Radiopharma Ltd (Hungary)
  • Nordion Inc (Canada)
  • Peregrine Pharmaceuticals, Inc. (US)
  • PETNET Solutions Inc (US)
  • Positron Corporation (US)
  • Singapore Radiopharmaceuticals Pte Ltd (Singapore)
  • Triad Isotopes, Inc. (US)

13. GLOBAL MARKET PERSPECTIVE

    • Table 13: World Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 14: World Historic Review for Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 15: World 15-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American for 2005, 2013 & 2018 (includes corresponding Graph/Chart)
    • Table 16: World Recent Past, Current & Future Analysis for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 17: World Historic Review for Diagnostic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 18: World 15-Year Perspective for Diagnostic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets for 2005, 2013 & 2018 (includes corresponding Graph/Chart)
    • Table 19: World Recent Past, Current & Future Analysis for Therapeutic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 20: World Historic Review for Therapeutic Radiopharmaceuticals by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets Independently Analyzed with Annual Sales in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 21: World 15-Year Perspective for Therapeutic Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Middle East and Latin American Markets for 2005, 2013 & 2018 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Outlook
    • Industry Structure
      • Production Scenario
      • Dependence on Imports
      • DOE's Flawed Isotope Program Causes Shortage Fears in the US
    • Regulatory Scenario
      • Thorny Regulations Dampen New Product Development
      • FDA's Antidote
    • Overview of Medicare Reimbursements
    • Medicare Payment Settings for Contrast Agents and Radiopharmaceuticals
      • Payments for Radiology Services
      • Medicare Coverage
      • Billing and Payment on Medicare Professional Claims
      • Payment Conditions for Radiology Services
      • Services Furnished in Hospitals to Inpatients
      • Services Furnished in Hospitals to Outpatients
      • Services Furnished in Skilled Nursing Facilities (SNF)
      • Services Furnished by Rural Health Clinics (RHC) and Federally Qualified Health Centers (FQHC)
      • Implications of Reimbursement Changes on Radiology
    • Radiopharmaceutical Reimbursement in the US: Who's Under the Umbrella
      • Diagnostic Radiopharmaceuticals Bundled As Supplies under Medicare Reimbursements
      • Concerns over Bundling of Zevalin into Diagnostic Radiopharmaceuticals Allayed
      • Improved Reimbursement for Therapeutic Radiopharmaceuticals
    • Market Overview
      • Sanguine Growth On Cards
      • Expanding Diagnostic Applications Will Stimulate Future Growth
      • Nuclear Cardiology Products Drive Up Diagnostic Radiopharmaceuticals Market
      • Cardiovascular Imaging To Lead Volume Growth
      • Cardiolite Loses Market Share to Generics
    • Table 22: The US Diagnostic Radiopharmaceutical Agents Market (2012): Percentage Share Breakdown of Procedure Volume by Imaging Procedure - SPECT and PET (includes corresponding Graph/Chart)
    • Table 23: US Market for Diagnostic Radiopharmaceuticals Agents (2012): Percentage Share Breakdown of Value Sales for Cardiology and Non-Cardiology Applications (includes corresponding Graph/Chart)
    • Table 24: US Market for Cardiology Diagnostic Radiopharmaceuticals (2010): Percentage Share Breakdown of SPECT Myocardial Perfusion Imaging (MPI) Procedure Volume by Imaging Agent - Cardiolite, Myoview, Thallium, and Sestamibi (includes corresponding Graph/Chart)
      • New Oncology, Neurology Agents to Boost Diagnostic Radiopharmaceuticals Market
    • Table 25: US Market for Non-Cardiology Diagnostic Radiopharmaceuticals Agents (2012): Percentage Share Breakdown of Value Sales for Oncology and Non-Oncology Applications (includes corresponding Graph/Chart)
      • Installed Base of SPECT Scanners
    • Table 26: Diagnostic Radiopharmaceutical Market in North America: Installed Base for SPECT and SPECT/CT Scanners in Units for Years 2006, 2008, 2010, 2012 & 2014 (includes corresponding Graph/Chart)
      • Installed Pet Scanners in US
      • US FDG Market
    • Table 27: US FDG Market (2012): Percentage Share Breakdown of Procedure Volume by Procedure Type - Oncology, Neurology and Cardiology (includes corresponding Graph/Chart)
      • Focused R&D Efforts will Fuel Therapeutic Radiopharmaceuticals Market
    • Market Share Statistics
    • Table 28: US Market for Diagnostic Radiopharmaceuticals Agents (2011): Percentage Market Share Breakdown for Leading Players (includes corresponding Graph/Chart)
    • Table 29: US Market for Therapeutic Radiopharmaceuticals (2012): Percentage Share Breakdown of Value Sales by Key Radiotherapeutics - Bone Palliation, Non-Hodgkin's Lymphoma, Hyperthyroidism /Thyroid Cancer and Others (includes corresponding Graph/Chart)
    • Table 30: US Market for Therapeutic Radiopharmaceutical Agents (2010): Percentage Market Share Breakdown of Leading Players (includes corresponding Graph/Chart)
    • Table 31: US Market for Radiopharmaceutical Bone Palliation Procedures (2012): Percentage Share Breakdown by Key Radiotherapeutics - Metastron, Quadramet and Sr-89 (includes corresponding Graph/Chart)
    • Table 32: Radiopharmacy Market in the US (2012): Percentage Breakdown of Revenues Generated by General Radiopharmacies and FDG Radiopharmacies (includes corresponding Graph/Chart)
    • Product Launches
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 33: US Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 34: US Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 35: US 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Outlook
    • Canadian Scientists Lead the Discovery of Remedy for Supply Shortages
    • An Overview of Medical Imaging Market
    • Regulatory and Legal Restrictions
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 36: Canadian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 37: Canadian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 38: Canadian 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Outlook
    • Reimbursement Issues
    • Japanese Healthcare System: An Overview
      • Fast Facts
    • Government Initiatives
  • B. Market Analytics
    • Table 39: Japanese Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 40: Japanese Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 41: Japanese 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • Competitive Scenario
    • Key Statistics
    • Table 42: European Radiopharmaceuticals Market (2010): Percentage Share Breakdown of Revenues by Company (includes corresponding Graph/Chart)
    • Table 43: European Diagnostic Radiopharmaceuticals Market (2012): Percentage Share Breakdown of Value Sales by Imaging Modalities - SPECT and PET (includes corresponding Graph/Chart)
    • Market Trends
      • New Applications and Products Augur Good Market Prospects
      • Increasing PET and PET/CT Applications Will Kindle Growth
  • B. Market Analytics
    • Table 44: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 45: European Historic Review for Radiopharmaceuticals by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 46: European 15-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
    • Table 47: European Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 48: European Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 49: European 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Outlook
    • Growth Stimulants
  • B. Market Analytics
    • Table 50: French Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 51: French Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 52: French 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Outlook
  • B. Market Analytics
    • Table 53: German Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 54: German Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 55: German 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

4c. ITALY

  • A. Market Analysis
    • Outlook
  • B. Market Analytics
    • Table 56: Italian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 57: Italian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 58: Italian 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Outlook
    • Strategic Corporate Development
    • Select Players
  • B. Market Analytics
    • Table 59: UK Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 60: UK Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 61: UK 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

4e. SPAIN

  • A. Market Analysis
    • Outlook
    • Recent Industry Activity
  • B. Market Analytics
    • Table 62: Spanish Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 63: Spanish Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 64: Spanish 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

4f. RUSSIA

  • A. Market Analysis
    • Outlook
  • B. Market Analytics
    • Table 65: Russian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 66: Russian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 67: Russian 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

4g. REST OF EUROPE

  • A. Market Analysis
    • Outlook
    • Market Overview
    • Strategic Corporate Developments
    • Select players
  • B. Market Analytics
    • Table 68: Rest of Europe Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 69: Rest of Europe Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 70: Rest of Europe 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Outlook
    • ANSTO: Leading the Radiopharmaceuticals Market
  • B. Market Analytics
    • Table 71: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Geographic Region - China, India and Rest of Asia-Pacific Markets Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 72: Asia-Pacific Historic Review for Radiopharmaceuticals by Geographic Region - China, India and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 73: Asia-Pacific 15-Year Perspective for Radiopharmaceuticals by Geographic Region - Percentage Breakdown of Value Sales for India, China and Rest of Asia-Pacific Markets for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
    • Table 74: Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 75: Asia-Pacific Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 76: Asia-Pacific 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

5a. CHINA

  • A. Market Analysis
    • Outlook
    • Medical Imaging Device Market - An Overview
    • Increasing Expenditure on Healthcare Sector
  • B. Market Analytics
    • Table 77: Chinese Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 78: Chinese Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 79: Chinese 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

5b. INDIA

  • A. Market Analysis
    • Outlook
    • Department of Atomic Energy Controls the Supply
    • Product Launch
    • Jubilant Life Sciences Limited - A Key Player
  • B. Market Analytics
    • Table 80: Indian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 81: Indian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 82: Indian 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

5c. REST OF ASIA-PACIFIC

  • A. Market Analysis
    • Outlook
    • Singapore Radiopharmaceuticals Pte Ltd - A Key Player
  • B. Market Analytics
    • Table 83: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 84: Rest of Asia-Pacific Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 85: Rest of Asia-Pacific 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

6. MIDDLE EAST

  • A. Market Analysis
    • Outlook
  • B. Market Analytics
    • Table 86: Middle East Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 87: Middle East Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 88: Middle-East 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

7. LATIN AMERICA

  • A. Market Analysis
    • Outlook
  • B. Market Analytics
    • Table 89: Latin American Recent Past, Current & Future Analysis for Radiopharmaceuticals by Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 90: Latin American Historic Review for Radiopharmaceuticals by Region - Brazil and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 91: Latin American 15-Year Perspective for Radiopharmaceuticals by Region - Percentage Breakdown of Value Sales for Brazil and Rest of Latin America for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)
    • Table 92: Latin American Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 93: Latin American Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 94: Latin American 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

7a. BRAZIL

  • A. Market Analysis
    • Outlook
  • B. Market Analytics
    • Table 95: Brazilian Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 96: Brazilian Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 97: Brazilian 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

7b. REST OF LATIN AMERICA

  • A. Market Analysis
    • Outlook
  • B. Market Analytics
    • Table 98: Rest of Latin America Recent Past, Current & Future Analysis for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2010 through 2018 (includes corresponding Graph/Chart)
    • Table 99: Rest of Latin America Historic Review for Radiopharmaceuticals by Segment - Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2004 through 2009 (includes corresponding Graph/Chart)
    • Table 100: Rest of Latin America 15-Year Perspective for Radiopharmaceuticals by Segment - Percentage Breakdown of Value Sales for Diagnostic Radiopharmaceuticals and Therapeutic Radiopharmaceuticals for Years 2005, 2013 & 2018 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Show More
Pricing